What is Revolution Medicines?
Revolution Medicines is a specialized biopharmaceutical enterprise dedicated to the discovery and development of targeted therapies for RAS-driven malignancies. By leveraging its unique tri-complex technology platform, the company addresses some of the most challenging targets in oncology. Its market position is defined by a commitment to precision medicine, aiming to deliver highly specific inhibitors that disrupt the signaling pathways of mutated RAS proteins, which are implicated in a wide range of aggressive cancers. The firm operates at the intersection of advanced molecular biology and therapeutic innovation, positioning itself as a critical player in the future of cancer care.
How much funding has Revolution Medicines raised?
Revolution Medicines has raised a total of $579.9M across 4 funding rounds:
Series A
$25M
Series B
$56M
Stock Offering
$238M
Stock Offering
$260.9M
Series A (2016): $25M with participation from The Column Group and Third Rock Ventures
Series B (2018): $56M led by Nextech Invest, Third Rock Ventures, The Column Group, Casdin Capital, and Schroder Adveq
Stock Issuance/Offering (2020): $238M, investors not publicly disclosed
Stock Issuance/Offering (2021): $260.9M, investors not publicly disclosed
Key Investors in Revolution Medicines
Nextech Invest
A Zurich-based firm dedicated to accelerating advancements in precision medicine by identifying and nurturing transformative cancer medicine companies during critical stages of scientific validation.
Third Rock Ventures
A healthcare venture firm focused on disruptive science and medicine, specializing in building companies that translate bold ideas into successful business enterprises with a focus on patient outcomes.
The Column Group
A venture ecosystem in the life sciences sector that employs an edge-to-edge investment model to support early-stage technology platforms and later-stage programs through to exit.
What's next for Revolution Medicines?
With the recent capital injection, Revolution Medicines is well-positioned to scale its clinical operations and broaden its therapeutic reach. The strategic focus will likely center on accelerating the clinical trial progression of its lead candidates, while simultaneously refining its tri-complex platform to identify new therapeutic targets. As the company matures, the emphasis will shift toward navigating regulatory pathways and establishing commercial readiness, ensuring that its precision oncology medicines can effectively reach the patient populations that need them most. Continued investment in R&D will remain the cornerstone of its long-term value creation strategy.
See full Revolution Medicines company page
